摘要
目的:观察莫西沙星联合抗痨药物化疗方案治疗耐多药肺结核(MDR-TB)的临床疗效和安全性。方法:84例MDR-TB患者随机分为两组:治疗组(n=42)采用莫西沙星(M)联合对氨基水杨酸异烟肼片(D)、利福喷丁(L)、吡嗪酰胺(Z)、乙胺丁醇(E);对照组(n=42)采用左氧氟沙星(V)联合D、L、Z、E;疗程均为18个月。观察和比较两组不同时期痰菌阴转率、临床疗效及不良反应发生率。结果:疗程结束时,治疗组痰菌阴转率为90.5%、空洞闭合率为58.6%,临床总有效率为83.3%,均显著高于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论:莫西沙星联合抗痨药物化疗方案治疗MDR-IB能加速痰菌阴转、加快空洞闭合,临床疗效显著。
Objective：To observe the clinical efficacy and safety of the chemotherapy of multidrug-resistant tuber-culosis （MDR-TB） with moxifloxaein combined with anti-tuberculosis drugs. Methods：84 MDR-TB patients were randomly divided into two groups. The treatment group （n = 42 ） were treated with moxifloxaein （M） joint pasiniazid （D） , rifapenti-ni （ L）, pyrazinamide （Z） and ethambutol （ E）, and the controlled group （ n = 42 ）, treated with levofloxaein （ V ） joint D, L, Z, E for a course of 18 months, respectively. Their phlegm germ feminine changed incidence rate, clinical efficacy and adverse reactions in different periods were observed and compared. Results：At the end of the treatment, the sputum negative conversion rate （90.5%） and cavity closure rate （58.6%） were significantly higher in the treatment group than those （73.8%, 32.1% ） in the controlled group（P 〈 0.05 ）. The incidence rates of clinical adverse reactions in the treatment group and controlled group were 33.3% and 31%, respectively. There were no statistical differences in the two groups（P 〉 0.05 ） . Conclusion： Moxifloxacin combined with anti-tuberculosis drugs chemotherapy in the treatment of MDR-TB could
出处
《药物流行病学杂志》
CAS
2014年第2期77-79,共3页
Chinese Journal of Pharmacoepidemiology
关键词
莫西沙星
肺结核
耐多药
Moxifloxacin
Tuberculosis
Multi-drug resistance
